SpyGlass Pharma, Inc. (SGP) Ownership
SGP ownership summary
as of October 18, 2026- Institutions
- 94.7% of shares outstanding
- Insiders
- 4.28% of shares outstanding
- Shares outstanding
- 33.4M
- Float
- 6.5M shares available to trade
- Short interest
- 11.29% 1.3M shares short
- Days to cover
- 8.86 short interest up 2.0% vs prior month
- Institutions 94.68%
- Insiders 4.28%
- Other investors 1.04%
SGP top institutional holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | RA Capital Management, LLC | 23.98% | 8.0M | $192.5M | — | June 30, 2026 |
| 2 | NEA Management Company, LLC | 22.10% | 7.4M | $177.4M | — | June 30, 2026 |
| 3 | Sands Capital Ventures, LLC | 7.47% | 2.5M | $60.0M | — | June 30, 2026 |
| 4 | Samsara BioCapital, LLC | 6.31% | 2.1M | $50.6M | — | June 30, 2026 |
| 5 | BlackRock Inc | 2.13% | 712K | $17.1M | +566,973 (+391.7%) | June 30, 2026 |
| 6 | T. Rowe Price Associates, Inc. | 2.02% | 674K | $16.2M | −30,297 (−4.3%) | June 30, 2026 |
| 7 | Vestal Point Capital LP | 2.00% | 670K | $16.1M | +3,240 (+0.5%) | June 30, 2026 |
| 8 | JPMorgan Chase & Co | 1.88% | 630K | $15.1M | +52,630 (+9.1%) | June 30, 2026 |
| 9 | Deerfield Management Co | 1.64% | 550K | $13.2M | — | June 30, 2026 |
| 10 | Millennium Management LLC | 1.52% | 507K | $12.2M | +38,463 (+8.2%) | June 30, 2026 |
| 11 | Aberdeen Group PLC | 1.47% | 493K | $11.8M | +272,622 (+123.7%) | June 30, 2026 |
| 12 | Vanguard Capital Management, LLC | 1.30% | 434K | $10.4M | −390 (−0.1%) | June 30, 2026 |
| 13 | Geode Capital Management, LLC | 0.83% | 277K | $6.7M | +150,785 (+119.2%) | June 30, 2026 |
| 14 | Franklin Templeton Inc | 0.70% | 233K | $5.6M | −66,588 (−22.2%) | June 30, 2026 |
| 15 | Affinity Asset Advisors, LLC | 0.39% | 132K | $3.2M | −118,414 (−47.4%) | June 30, 2026 |
| 16 | State Street Corp | 0.35% | 118K | $2.8M | +100,311 (+581.5%) | June 30, 2026 |
| 17 | Charles Schwab Investment Management Inc | 0.26% | 86K | $2.1M | +26,071 (+43.7%) | June 30, 2026 |
| 18 | Northern Trust Corp | 0.25% | 82K | $2.0M | +61,589 (+295.2%) | June 30, 2026 |
| 19 | Vanguard Portfolio Management, LLC | 0.23% | 76K | $1.8M | +72,132 (+1,960.1%) | June 30, 2026 |
| 20 | Vanguard Fiduciary Trust Co | 0.20% | 68K | $1.6M | +8,716 (+14.6%) | June 30, 2026 |
Value at the latest close. Change = shares bought or sold in the latest quarterly filing (13F). In the top 20, 11 holders added 1.4M shares and 4 cut 216K.
SGP top mutual fund and ETF holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | JPMorgan Small Cap Growth A | 1.39% | 464K | $11.1M | −13,686 (−2.9%) | August 31, 2026 |
| 2 | Vanguard MStar Total Stk Mkt Idx Invest | 0.95% | 317K | $7.6M | — | August 31, 2026 |
| 3 | abrdn Healthcare Investors | 0.66% | 222K | $5.3M | — | August 31, 2026 |
| 4 | T. Rowe Price New Horizons | 0.63% | 209K | $5.0M | −8,550 (−3.9%) | August 31, 2026 |
| 5 | JPMorgan Small Cap Blend A | 0.44% | 149K | $3.6M | −4,867 (−3.2%) | August 31, 2026 |
| 6 | abrdn Healthcare Opportunities | 0.40% | 135K | $3.3M | — | August 31, 2026 |
| 7 | Fidelity Small Cap Index | 0.36% | 121K | $2.9M | +1,127 (+0.9%) | July 31, 2026 |
| 8 | abrdn World Healthcare | 0.32% | 108K | $2.6M | — | August 31, 2026 |
| 9 | Franklin Biotechnology Discovery A | 0.25% | 85K | $2.0M | +84,708 (0.0%) | August 31, 2026 |
| 10 | Vanguard Russell 2000 ETF | 0.19% | 64K | $1.5M | +1,320 (+2.1%) | August 31, 2026 |
| 11 | JPM US Small Cap Growth A dist USD | 0.16% | 52K | $1.3M | −342 (−0.7%) | August 31, 2026 |
| 12 | Fidelity Extended Market Index | 0.15% | 50K | $1.2M | +1,038 (+2.1%) | August 31, 2026 |
| 13 | ALPS Medical Breakthroughs ETF | 0.13% | 44K | $1.1M | — | September 30, 2026 |
| 14 | abrdn Life Sciences Investors | 0.12% | 41K | $979,824 | — | August 31, 2026 |
| 15 | Schwab US Small-Cap ETF™ | 0.11% | 35K | $846,888 | +18 (+0.1%) | September 30, 2026 |
| 16 | JPM US Small Cap Growth C Acc | 0.11% | 35K | $844,536 | −3 (−0.0%) | August 31, 2026 |
| 17 | Schwab Small Cap Index | 0.08% | 27K | $644,712 | — | August 31, 2026 |
| 18 | TD Health Sciences - I | 0.07% | 24K | $570,960 | — | June 30, 2026 |
| 19 | JPMorgan American Ord | 0.07% | 24K | $567,024 | +9,498 (+67.2%) | July 31, 2026 |
| 20 | Fidelity Total Market Index | 0.07% | 23K | $550,824 | — | August 31, 2026 |
Funds report holdings monthly or quarterly; dates differ by fund.
SGP insider transactions
latest 1| Date | Name | Transaction | Price | Shares | Value |
|---|---|---|---|---|---|
| 2026-02-09 | Ra Capital Management, L.P. | Buy | $16.00 | 3,690,000 | $59.0M |
Reported trades by company officers, directors and other filers (including disclosures by members of Congress where EODHD lists them). "—" where the filing gives no share count.
Who owns SGP
Institutional investors own 94.7% of SpyGlass Pharma's shares and insiders 4.28%. The largest holder is RA Capital Management, LLC with 23.98% of the shares (8.0M), as of June 30, 2026. Among the top 20 institutions, 11 added shares and 4 reduced their stake in the latest filings. Short interest is 11.29% of the float, or 8.86 days of average trading volume. The share count rose 4.7% since 2024.
Related: SGP analyst forecast, SGP key metrics. See the SGP stock overview for the latest quote and news.
SGP ownership FAQ
Who owns the most SpyGlass Pharma stock?
The largest shareholders of SpyGlass Pharma are RA Capital Management, LLC (23.98%), NEA Management Company, LLC (22.10%), Sands Capital Ventures, LLC (7.47%), Samsara BioCapital, LLC (6.31%), BlackRock Inc (2.13%).
What percentage of SpyGlass Pharma is owned by institutions?
Institutions hold 94.7% of SpyGlass Pharma's shares outstanding; insiders hold 4.28%.
Which funds own SpyGlass Pharma?
The largest fund holders of SpyGlass Pharma are JPMorgan Small Cap Growth A (1.39%), Vanguard MStar Total Stk Mkt Idx Invest (0.95%), abrdn Healthcare Investors (0.66%), T. Rowe Price New Horizons (0.63%), JPMorgan Small Cap Blend A (0.44%).
What is SpyGlass Pharma's short interest?
1.3M shares of SpyGlass Pharma were sold short, 11.29% of the float; at the average daily volume it would take 8.86 days to cover.
Are insiders buying or selling SpyGlass Pharma?
Of the latest 1 reported insider transactions in SpyGlass Pharma (since February 9, 2026), 1 were purchases and 0 were sales.
How many shares of SpyGlass Pharma are outstanding?
SpyGlass Pharma has 33.4M shares outstanding, of which 6.5M are in the public float.